Development and characterization of L-HSA conjugated PLGA nanoparticle for hepatocyte targeted delivery of antiviral drug

Dhoke, Dipali M.; Basaiyye, Shriniwas S.; Khedekar, Pramod B.

doi:10.1016/j.jddst.2018.06.006

Cited by 21 publications

(15 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HSA can react with small molecular drugs, NPs, and drugloaded NPs [40][41][42]. However, a number of fundamental principles have not been elucidated, including the binding force, binding coefficient, type of reaction, relationship between active and passive adsorption, and characteristics of their interactions [43][44][45].…”

Section: Discussionmentioning

confidence: 99%

Interaction of Mitoxantrone-Loaded Cholesterol Modified Pullulan Nanoparticles with Human Serum Albumin and Effect on Drug Release

Yuan

Guo

Zhong

et al. 2019

Journal of Nanomaterials

View full text Add to dashboard Cite

To clarify nanoparticle-protein interaction and their action characteristics, the interactions between MTO-CHP NPs and human serum albumin (HSA) were studied by isothermal titration calorimetry (ITC), fluorescence spectroscopy, dynamic light scattering (DLS), and circular dichroism spectroscopy (CD). Hydrophobically modified pullulan (CHP) nanoparticles (NPs) loaded with mitoxantrone (MTO) were prepared (MTO-CHP NPs) with size 166.9 nm. The spherical shape was verified by transmission electron microscopy (TEM). The ITC results demonstrated an interaction between MTO-CHP NPs mainly by hydrophobic interaction force, electrostatic force, and hydrogen bonding. The mean binding constant KA was 0.832×104 M−1 and mean HSA coverage 0.939±0.302. MTO-CHP NPs could quench the fluorescence intensity of HSA, which gradually decreased to be balanced in 9 h and indicated the completion of the complexation. The size and zeta potential changes of the combined particle were dynamically detected with DLS at 0, 3, 6, 9, 12, 15, and 18 h. When the reaction was completed at 9 h, the particle size and potential remained stable, accompanied by a size change from 89.91 to about 145 nm and potential change from -15 to -3 mV, respectively. The results of CD measurement showed that the change in ellipticity of HSA at 208 nm was similar to the fluorescence spectra and DLS measurements with MTO-CHP NPs combined with HSA. At the beginning of the reaction, the proportion of α-helix was 52.3% to 43.7%, which decreased by 39.1% at compound stabilization. The release of MTO from MTO-CHP NPs at pH=5.6 was significantly accelerated, whereas that of MTO from HSA-MTO-CHP NPs was significantly reduced, and the drug release was significantly slowed down even under acidic conditions, which indicates the beneficial effect of HSA on the persistence and stability of the HSA-MTO-CHP NP compound.

show abstract

Section: Discussionmentioning

confidence: 99%

Interaction of Mitoxantrone-Loaded Cholesterol Modified Pullulan Nanoparticles with Human Serum Albumin and Effect on Drug Release

Yuan

Guo

Zhong

et al. 2019

Journal of Nanomaterials

View full text Add to dashboard Cite

show abstract

“…Antiviral drugs are active molecules used for treating viral infections. [74] Although most of these agents are designed to target specific viruses, it is still possible to find drugs that are effective against a wide range of viruses. [75] The mechanism of antiviral drugs is presented in Figure 7.…”

Section: Antiviral Deliverymentioning

confidence: 99%

“…Adoption of nanoparticle delivery platforms provides the possibility of targeting specific biological sites either passively or actively. [ 74 ]…”

Section: Antiviral Deliverymentioning

confidence: 99%

Drug Delivery (Nano)Platforms for Oral and Dental Applications: Tissue Regeneration, Infection Control, and Cancer Management

et al. 2021

View full text Add to dashboard Cite

The oral cavity and oropharynx are complex environments that are susceptible to physical, chemical, and microbiological insults. They are also common sites for pathological and cancerous changes. The effectiveness of conventional locally-administered medications against diseases affecting these oral milieus may be compromised by constant salivary flow. For systemically-administered medications, drug resistance and adverse side-effects are issues that need to be resolved. New strategies for drug delivery have been investigated over the last decade to overcome these obstacles. Synthesis of nanoparticle-containing agents that promote healing represents a quantum leap in ensuring safe, efficient drug delivery to the affected tissues. Micro/nanoencapsulants with unique structures and properties function as more favorable drug-release platforms than conventional treatment approaches. The present review provides an overview of newly-developed nanocarriers and discusses their potential applications and limitations in various fields of dentistry and oral medicine.

show abstract

“…[36][37][38] For instance, the functionalization of PLGANPs with a maleimide-polyethylene glycol (PEG) improved plasma half-life by providing stealthiness towards reticuloendothelial system. [37] Valine functionalization of PLGA-PEG nanoparticles allowed its recognition by intestinal transporters improving the PLGA-PEG-valine nanoparticles residence time and enhanced the permeability of carried acyclovir. [38] PLGANPs have also been used as a carrier for combined antiviral drugs, encompassing up to three different antiviral drugs, and a formulation showed viability to be applied subcutaneously, which may adapt to a wearable injector device, which would help prevent patient nonadherence.…”

Section: Nanoparticles As Nanocarriers For Antiviral Drugsmentioning

confidence: 99%

Advanced Material Against Human (Including Covid‐19) and Plant Viruses: Nanoparticles As a Feasible Strategy

et al. 2020

View full text Add to dashboard Cite

The SARS‐CoV‐2 virus outbreak revealed that these nano‐pathogens have the ability to rapidly change lives. Undoubtedly, SARS‐CoV‐2 as well as other viruses can cause important global impacts, affecting public health, as well as, socioeconomic development. But viruses are not only a public health concern, they are also a problem in agriculture. The current treatments are often ineffective, are prone to develop resistance, or cause considerable adverse side effects. The use of nanotechnology has played an important role to combat viral diseases. In this review three main aspects are in focus: first, the potential use of nanoparticles as carriers for drug delivery. Second, its use for treatments of some human viral diseases, and third, its application as antivirals in plants. With these three themes, the aim is to give to readers an overview of the progress in this promising area of biotechnology during the 2017–2020 period, and to provide a glance at how tangible is the effectiveness of nanotechnology against viruses. Future prospects are also discussed. It is hoped that this review can be a contribution to general knowledge for both specialized and non‐specialized readers, allowing a better knowledge of this interesting topic.

show abstract

Development and characterization of L-HSA conjugated PLGA nanoparticle for hepatocyte targeted delivery of antiviral drug

Cited by 21 publications

References 72 publications

Interaction of Mitoxantrone-Loaded Cholesterol Modified Pullulan Nanoparticles with Human Serum Albumin and Effect on Drug Release

Interaction of Mitoxantrone-Loaded Cholesterol Modified Pullulan Nanoparticles with Human Serum Albumin and Effect on Drug Release

Drug Delivery (Nano)Platforms for Oral and Dental Applications: Tissue Regeneration, Infection Control, and Cancer Management

Advanced Material Against Human (Including Covid‐19) and Plant Viruses: Nanoparticles As a Feasible Strategy

Contact Info

Product

Resources

About